HI HB1767

Requires health insurers, mutual benefit societies, and health maintenance organizations to cover at least one generic opioid antagonist (such as naloxone) and delivery device for policyholders and dependents, effective January 1, 2027.

Generic opioid antagonists must be placed on the lowest cost-sharing tier of insurance formularies and cannot be subject to annual or lifetime dollar limitations.

Prior authorization is prohibited for generic opioid antagonists, though insurers may require prior authorization for non-generic (brand-name) versions.

Coverage must comply with the Mental Health Parity and Addiction Equity Act of 2008 regarding financial requirements and treatment limitations.

"Device" is defined to include nasal sprays, oral tablets, and auto-injectors used to administer opioid overdose reversal medications.